NO324249B1 - Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene - Google Patents

Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene

Info

Publication number
NO324249B1
NO324249B1 NO20024424A NO20024424A NO324249B1 NO 324249 B1 NO324249 B1 NO 324249B1 NO 20024424 A NO20024424 A NO 20024424A NO 20024424 A NO20024424 A NO 20024424A NO 324249 B1 NO324249 B1 NO 324249B1
Authority
NO
Norway
Prior art keywords
group
derivatives
hydroxy
intermediates
glycopyranosyloxybenzylbenzene
Prior art date
Application number
NO20024424A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024424L (no
NO20024424D0 (no
Inventor
Toshihiro Nishimura
Kenji Katsuno
Masahiro Hiratochi
Nobuhiko Fushimi
Kazyua Tatani
Yoshiki Tokutake
Masayuki Isaji
Hideki Fujikura
Original Assignee
Kissei Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18594892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO324249(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical Company filed Critical Kissei Pharmaceutical Company
Publication of NO20024424D0 publication Critical patent/NO20024424D0/no
Publication of NO20024424L publication Critical patent/NO20024424L/no
Publication of NO324249B1 publication Critical patent/NO324249B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
NO20024424A 2000-03-17 2002-09-16 Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene NO324249B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000077304 2000-03-17
PCT/JP2001/002041 WO2001068660A1 (fr) 2000-03-17 2001-03-15 Derives glucopyranosyloxybenzylbenzene, preparations medicinales les contenant et intermediaires pour la preparation desdits derives

Publications (3)

Publication Number Publication Date
NO20024424D0 NO20024424D0 (no) 2002-09-16
NO20024424L NO20024424L (no) 2002-11-18
NO324249B1 true NO324249B1 (no) 2007-09-17

Family

ID=18594892

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024424A NO324249B1 (no) 2000-03-17 2002-09-16 Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene

Country Status (28)

Country Link
US (3) US7465712B2 (bg)
EP (1) EP1270584B1 (bg)
JP (1) JP3773450B2 (bg)
KR (1) KR100660738B1 (bg)
CN (1) CN1177857C (bg)
AT (1) ATE312114T1 (bg)
AU (2) AU4114601A (bg)
BG (1) BG65867B1 (bg)
BR (1) BR0109323A (bg)
CA (1) CA2402609C (bg)
CZ (1) CZ20023023A3 (bg)
DE (1) DE60115623T2 (bg)
DK (1) DK1270584T3 (bg)
ES (1) ES2254376T3 (bg)
HK (1) HK1055973A1 (bg)
HU (1) HUP0300057A3 (bg)
IL (2) IL151757A0 (bg)
MX (1) MXPA02009034A (bg)
NO (1) NO324249B1 (bg)
NZ (1) NZ521369A (bg)
PL (1) PL205605B1 (bg)
RU (1) RU2254340C2 (bg)
SK (1) SK287183B6 (bg)
TR (1) TR200202200T2 (bg)
TW (1) TWI293305B (bg)
UA (1) UA72586C2 (bg)
WO (1) WO2001068660A1 (bg)
ZA (1) ZA200207418B (bg)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
SK287811B6 (sk) * 2000-09-29 2011-10-04 Kissei Pharmaceutical Co., Ltd Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu
US7053060B2 (en) 2000-11-30 2006-05-30 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
JPWO2003011880A1 (ja) * 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
BR0308653A (pt) * 2002-03-22 2005-02-15 Kissei Pharmaceutical Cristais de derivado de benzeno de glicopiranosiloxibenzila
US7956041B2 (en) * 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
BR0310006A (pt) 2002-08-09 2005-02-15 Taisho Pharmaceutical Co Ltd Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
JP4651934B2 (ja) * 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
UA86042C2 (en) * 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
EP1679965A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES
CN103819465A (zh) * 2003-08-01 2014-05-28 田边三菱制药株式会社 新颖化合物
AU2004261663A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
EP1680414A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDAZOLE-O-GLUCOSIDE
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US7371732B2 (en) * 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
BRPI0508830B8 (pt) * 2004-03-16 2021-05-25 Boehringer Ingelheim Int derivados de benzeno substituídos por glucopiranosila, medicamentos contendo esses compostos, seu uso e processo para sua fabricação
CA2560005A1 (en) * 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Phenol derivative, medicinal composition containing the same, and medicinal use thereof
US20080045466A1 (en) 2004-07-21 2008-02-21 Kenji Katsuno Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
CA2588963C (en) 2004-11-18 2013-06-25 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
CN101111508B (zh) * 2005-01-28 2011-03-30 中外制药株式会社 螺缩酮衍生物及其作为糖尿病治疗药物的用途
JP5073948B2 (ja) * 2005-01-31 2012-11-14 田辺三菱製薬株式会社 医薬組成物
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI365186B (en) 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
US7772191B2 (en) * 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
NZ573687A (en) 2006-05-19 2010-10-29 Taisho Pharmaceutical Co Ltd C-phenyl glycitol compound for the treatment of diabetes
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
JP5152519B2 (ja) 2006-06-29 2013-02-27 大正製薬株式会社 Ｃ−フェニル１−チオグルシト−ル化合物
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI432446B (zh) * 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TW200817424A (en) * 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
JPWO2008044762A1 (ja) 2006-10-13 2010-02-18 中外製薬株式会社 チオグルコーススピロケタール誘導体、およびその糖尿病治療薬としての使用
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
ES2397664T3 (es) 2006-12-04 2013-03-08 Janssen Pharmaceutica, N.V. Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
EP2103607A4 (en) 2006-12-14 2011-01-05 Taisho Pharmaceutical Co Ltd 1-phenyl-1-thio-D-GLUCITOLDERIVAT
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PT2183263E (pt) * 2007-07-26 2012-01-11 Lexicon Pharmaceuticals Inc Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio
PT2200606T (pt) 2007-09-10 2017-12-13 Janssen Pharmaceutica Nv Processo para a preparação de compostos úteis como inibidores de sglt
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2009096503A1 (ja) * 2008-01-31 2009-08-06 Daiichi Sankyo Company, Limited ベンジルフェニルグルコピラノシド誘導体
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
RS52236B (en) * 2008-08-28 2012-10-31 Pfizer Inc. DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CN101445528B (zh) * 2008-12-25 2011-06-15 天津药物研究院 硫代葡萄糖衍生物、其制备方法和用途
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
WO2011003976A1 (en) 2009-07-10 2011-01-13 Janssen Pharmaceutica Nv CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL] BENZENE
BR112012007085B8 (pt) * 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
CA2777528C (en) 2009-10-14 2018-09-18 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
CA2778384A1 (en) 2009-10-20 2011-04-28 Novartis Ag Glycoside derivative and uses thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
ES2527179T3 (es) 2009-11-02 2015-01-21 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011143296A1 (en) 2010-05-11 2011-11-17 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
AU2012230822A1 (en) 2011-03-23 2013-11-07 University Of Utah Research Foundation Methods for treating or preventing urological inflammation
PL2697218T3 (pl) 2011-04-13 2016-11-30 Sposób wytwarzania związków użytecznych, jako inhibitory SGLT2
AU2012241426A1 (en) 2011-04-14 2013-10-31 Novartis Ag Glycoside derivatives and uses thereof
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2014170383A1 (en) 2013-04-18 2014-10-23 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN105939157B (zh) * 2015-03-03 2019-08-06 卡西欧计算机株式会社 电平变换电路以及投影装置
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN113980071B (zh) * 2021-11-26 2023-08-22 重庆大学 红景天苷衍生物及其应用
CN114933619B (zh) * 2022-05-18 2024-03-01 上海科利生物医药有限公司 一类硫代糖苷列净类似物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549476B1 (fr) * 1983-07-20 1986-04-25 Rech Ind Benzyl-phenyl-osides, procede de preparation et utilisation en therapeutique
DE3718638A1 (de) * 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DK1213296T3 (da) * 1999-08-31 2004-08-16 Kissei Pharmaceutical Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method

Also Published As

Publication number Publication date
EP1270584A4 (en) 2003-04-09
PL358002A1 (en) 2004-08-09
SK12972002A3 (sk) 2003-07-01
NO20024424L (no) 2002-11-18
JP3773450B2 (ja) 2006-05-10
AU4114601A (en) 2001-09-24
IL151757A (en) 2009-02-11
CZ20023023A3 (cs) 2003-04-16
AU2001241146B2 (en) 2006-06-29
SK287183B6 (sk) 2010-02-08
IL151757A0 (en) 2003-04-10
BG107102A (bg) 2003-04-30
PL205605B1 (pl) 2010-05-31
NO20024424D0 (no) 2002-09-16
EP1270584A1 (en) 2003-01-02
KR100660738B1 (ko) 2006-12-22
NZ521369A (en) 2004-07-30
ES2254376T3 (es) 2006-06-16
RU2254340C2 (ru) 2005-06-20
TWI293305B (en) 2008-02-11
US20050080022A1 (en) 2005-04-14
DE60115623D1 (de) 2006-01-12
CA2402609C (en) 2010-06-15
CA2402609A1 (en) 2001-09-20
TR200202200T2 (tr) 2002-12-23
RU2002124873A (ru) 2004-01-10
BR0109323A (pt) 2002-12-24
US7045665B2 (en) 2006-05-16
DE60115623T2 (de) 2006-07-06
EP1270584B1 (en) 2005-12-07
US20040053855A1 (en) 2004-03-18
ATE312114T1 (de) 2005-12-15
BG65867B1 (bg) 2010-03-31
CN1418219A (zh) 2003-05-14
HK1055973A1 (en) 2004-01-30
US20050075294A1 (en) 2005-04-07
ZA200207418B (en) 2003-09-16
DK1270584T3 (da) 2006-04-18
HUP0300057A3 (en) 2003-09-29
HUP0300057A2 (en) 2003-05-28
WO2001068660A1 (fr) 2001-09-20
MXPA02009034A (es) 2003-09-10
AU2001241146B8 (en) 2006-07-27
KR20020086649A (ko) 2002-11-18
UA72586C2 (en) 2005-03-15
US7465712B2 (en) 2008-12-16
CN1177857C (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
NO324249B1 (no) Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene
DK1213296T3 (da) Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
MY129023A (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
IL166748A0 (en) Pyrazole derivative medicinal composition containing the same medicinal use thereof and intermediatefor production thereof
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
IL176546A0 (en) Imidazoline derivatives having cb1-antagonistic activity
AU4396899A (en) Remedies for diabetes
HK1061674A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
HUP0301561A2 (hu) Triazintrion-szulfoxidok alkalmazása kokcidiózis elleni készítmények elżállítására
EP1500656A4 (en) BIGUANIDE DERIVATIVE AND DIABETES TREATMENT AGENT CONTAINING
DE60211686D1 (de) Pkb-3564-substanz mit die gefässneubildung hemmender wirkung
UA84737C2 (ru) Производные имидазолина с антагонистической активностью относительно cb1

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees